Cahaba Pharmaceuticals

Cahaba Pharmaceuticals develops novel therapeutics and supportive care products for cancer patients.

Cahaba Pharmaceuticals, LLC, a biotech company, focuses on the development of oncology therapeutics and supportive care products for cancer patients. Its products include 1uracil topical ointment, a dihydropyrimidine dehydrogenase inhibitor for the treatment of hand-foot syndrome; and triciribine phosphate monohydrate, a nucleoside analog inhibition of AKT, a key component of a signaling pathway to promote cancer cell growth and survival, and resistance to chemotherapy and radiotherapy. The company was founded in 2008 and is based in Princeton, New Jersey.